WHO WE ARE

We are a preclinical-stage therapeutics company leveraging human-identical molecules as new medicines to treat large patient populations underserved by current treatment options. Our initial drug candidates are based on bioactive oligosaccharides naturally produced in human milk, or HMOs, which directly modulate the immune system and other human cells as well as the gut microbiome.

We believe our synthetic biology-manufactured human-identical milk oligosaccharide, or HiMO, drug candidates have the potential to affect multiple pathways implicated in gut-brain axis disorders and certain inflammatory disorders, while reproducing the favorable safety and tolerability profile observed of HMOs. We are prioritizing the development of our drug candidates for disorders where available treatment options are inadequately serving patients due to safety or tolerability issues and where we have the potential to redefine the standard of care.

Our Team

Alex Martinez

CEO, Chairman & Co - Founder

An entrepreneur inspired to make a public health impact informed by his own patient journey.
More Info

Jason Ferrone

COO, President & Co - Founder

An industry veteran with a unique combination of leadership experience across unlikely disciplines with a desire to innovate a culture aligned with the medicines we are developing.
More Info

Emil Chuang

MB BS, (Syd), FRACP, Chief Medical Officer

Pediatric gastroenterologist with a passion for developing safe and effective medicines with broad potential to modulate the gut microbiome and be translated to both adults and children.
More Info

Dustin Crawford

General Counsel and VP, Corporate Development

Dustin has served as our General Counsel, Vice President, Legal & Corporate Development and Secretary since September 2021, prior to which he consulted for the Company as the external head of Corporate Development since October 2020.
More Info

David Donahue

VP, Clinical Operations

Dave has over 30 years of experience in clinical development spanning pharmaceutical, biotech, and Medical devices in the therapeutic areas.
More Info

Michelle David

MBA, Director, Operations and Corporate Development

A business leader inspired by visionary healthcare with a motivation to scale organizations by finding and maintaining balance in the disorganization inherently produced by company growth and development.
More Info

Alyssa Palmquist

MBS, Associate Director, Corporate Affairs and Patient Engagement

An industry professional with unique experience at the intersection of science, marketing, and corporate affairs with a passion for understanding novel science and connecting with individuals who suffer from difficult to treat medical conditions.
More Info

Nichole Ghazanfarpour

Executive Assistant

An Executive Assistant who is driven by making processes run efficiently and effectively to maintain productivity even in the most challenging situations, is ever resourceful and adaptable, and is eager to serve as a trusted manager, organizer, advisor, and mentor.
More Info

Board of Directors

Alex Martinez
CEO, Chairman & Co - Founder
Jason Ferrone
COO, President & Co - Founder

Scientific Advisory Board

Angela Christiano, PhD
Professor at Columbia University Medical Center
David Newburg, PhD
One of the founding members of Glycosyn and the Chairman of Glycosyn Scientific Advisory Board
John McCoy, PhD
Chief Scientific Officer of Glycosyn
Ardythe Morrow, PhD
Professor of Epidemiology and Pediatrics at the University of Cincinnati College of Medicine and Cincinnati Children's Hospital Medical Center

Medical Advisory Board

Brian Lacy, MD, PhD
Consultant and Professor of Medicine at Mayo Clinic Jacksonville
Anthony Lembo, MD
Director of the GI Motility and Functional Bowel Disorders Program at Beth Israel Deaconess Medical Center and Associate Professor of Medicine at Harvard Medical School in Boston, MA
Nicholas Talley, MD, PhD
Distinguished Laureate Professor & Director of the NHMRC Centre of Research Excellence in Digestive Health at the University of Newcastle, Australia
Purna Kashyap, MB BS, PhD
Professor of Medicine and Physiology, Co- Director of the Microbiome program and High Definition Therapeutics program and Director of the germ-free mouse facility at Mayo Clinic, Rochester, MN
Baharak Moshiree
Professor of Medicine and Director of Motility, in the Division of Gastroenterology at the University of North Carolina, Atrium Health, in Charlotte, NC
Daniel Lovell, MD
Associate Director, Division of Rheumatology & Professor, UC Department of Pediatrics
Steve Hughes, MD
Chief Medical Officer, Avidity Biosciences